Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Invested Capital (2019 - 2025)

BioNexus Gene Lab's Return on Invested Capital history spans 7 years, with the latest figure at 0.32% for Q3 2025.

  • Quarterly results put Return on Invested Capital at 0.32% for Q3 2025, down 23.0% from a year ago — trailing twelve months through Sep 2025 was 0.32% (down 23.0% YoY), and the annual figure for FY2024 was 0.17%, up 14.0%.
  • Return on Invested Capital for Q3 2025 was 0.32% at BioNexus Gene Lab, up from 0.38% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.11% in Q4 2021 to a low of 0.41% in Q3 2023.
  • The 5-year median for Return on Invested Capital is 0.09% (2024), against an average of 0.12%.
  • The sharpest move saw Return on Invested Capital crashed -39bps in 2023, then skyrocketed 32bps in 2024.
  • Year by year, Return on Invested Capital stood at 0.11% in 2021, then tumbled by -147bps to 0.05% in 2022, then tumbled by -426bps to 0.27% in 2023, then soared by 36bps to 0.17% in 2024, then tumbled by -83bps to 0.32% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.32%, 0.38%, and 0.26% for Q3 2025, Q2 2025, and Q1 2025 respectively.